News

Targeted Oncology13h
OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology1d
Vepdegestrant Shows PFS Advantage in ESR1-Mutant ER+/HER2− Breast Cancer
Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...
New Scientist1d
The chilling discovery that nerve cells help cancers grow and spread
A new understanding of how tumours exploit our nervous system is leading to new ways to treat cancer using familiar drugs ...
Study reveals new indicators for HER2+ breast cancer response to therapy
Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...
Mirage News5d
Research Uncovers New HER2+ Breast Cancer Therapy Markers
Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...
Frontiers5d
SSTP1, a Host Defense Peptide, Exploits the Immunomodulatory IL6 Pathway to Induce Apoptosis in Cancer Cells
In contrast to the IL6 blockers inhibiting JAK/STAT activity, SSTP1 shifts the proliferative IL6/JAK/STAT signaling to the apoptotic IL6/JNK/AP1 pathway. In IL6Rα-overexpressing cancer cells, SSTP1 ...